Breakthrough CAR-T Therapy Keeps HIV in Check Without Daily Pills

Imagine living with HIV without the lifelong burden of daily antiretroviral drugs. For two patients in a groundbreaking trial, that’s now reality, thanks to CAR-T cell therapy, the same tech revolutionizing cancer treatment.

In a first-of-its-kind human study presented this week at the American Society of Gene and Cell Therapy meeting in Boston, researchers from UCSF, UC Davis, Case Western Reserve, and nonprofit Caring Cross infused patients with their own immune cells, genetically tweaked to hunt HIV. The therapy targets two key spots on the virus, CD4 and CCR5, letting the supercharged T cells both destroy infected cells and dodge HIV infection themselves.

Of nine participants, two saw HIV drop to undetectable levels after stopping standard meds: one for over two years, the other nearly a year. A third kept the virus at very low, detectable levels post-rebound. Unlike cancer CAR-T treatments, side effects here were mild, with no severe inflammation.

“We saw sustained control in people treated early after infection,” said UCSF’s Dr. Steven Deeks, the lead investigator. Patient “John” (a pseudonym), diagnosed soon after exposure, called it “life-changing freedom.”

The path to scalability? Caring Cross aims to slash costs, making it accessible beyond rare cases like the handful of “cured” patients via risky bone marrow transplants. Larger trials are next, but experts hail this as proof that a one-time shot could transform HIV management.

Experts caution: It’s early days, and not everyone responded fully. Still, for the 39 million living with HIV worldwide, this small study lights a big path forward.